Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Series B brings in $37.5mm for Applied Genetic Technologies

Executive Summary

Applied Genetic Technologies Corp. (gene therapies for retinal diseases) has raised $37.5mm through its Series B venture round. Alta Partners and SR One led the financing and was joined by new investor Osage University Partners and current shareholders InterWest, Intersouth Partners, and MedImmune Ventures. The company will use the money to continue developing a Phase II alpha-1 antitrypsin deficiency therapy and to start working on treatments for achromatopsia and x-linked rentinoschisis.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register